Harvard Gastroenterology Specialist Dr. Hamed Khalili Appointed to Vivante Health Clinical Advisory Board for Inflammatory Bowel Disease Research

Harvard Gastroenterology Specialist Dr. Hamed Khalili Joins Vivante Health Advisory Board Overview Company: Vivante Health Indication: Inflammatory Bowel Diseases Drug: N/A Trial Phase: N/A NCT ID: N/A Details Vivante Health has appointed Dr. Hamed Khalili to its Clinical Advisory Board to advance research in inflammatory bowel diseases. Dr. Khalili is a respected gastroenterologist at Massachus..

  • format_list_bulleted BS
  • · 2024. 2. 28.
  • textsms

Enhanced Risk Stratification in Stage I Melanoma Patients Achieved Using DecisionDx-Melanoma Test Over Traditional AJCC8 Methodology

Enhanced Risk Stratification in Stage I Melanoma Patients Using DecisionDx-Melanoma Overview Company: Castle Biosciences, Inc. Indication: Stage I Cutaneous Melanoma (CM) Drug/test: DecisionDx-Melanoma Test Trial Phase: Not Applicable NCT ID: Not Available Background Castle Biosciences, Inc. announced on February 26, 2024, a significant enhancement in risk stratification for Stage I Cutaneous Me..

  • format_list_bulleted BS
  • · 2024. 2. 28.
  • textsms

Preliminary Results Display Full Tumor Eradication in Non-surgical Breast Cancer Patients Using IceCure's ProSense® Cryoablation Therapy

Preliminary Results Display Full Tumor Eradication in Non-surgical Breast Cancer Patients Using IceCure's ProSense® Cryoablation Therapy Overview Company: IceCure Medical Ltd. Indication: Early-Stage Breast Cancer Drug/Treatment: ProSense® System Trial Phase: Not applicable NCT ID: Not available Study Summary In a groundbreaking study led by Dr. Federica di Naro at Azienda Ospedaliero-Universita..

  • format_list_bulleted BS
  • · 2024. 2. 28.
  • textsms

NewBiologix Engages with Florabio to Transform Gene Therapy Manufacturing through Advanced HEK293 Cell Line Engineering

NewBiologix Engages with Florabio to Transform Gene Therapy Manufacturing through Advanced HEK293 Cell Line Engineering Company: NewBiologix SA Indication: Not Applicable Drug: Recombinant adeno-associated virus (rAAV) vectors Trial Phase: Not Applicable NCT ID: Not Available Overview On February 27, 2024, NewBiologix SA, a biotech firm based in Lausanne, Switzerland, announced a strategic partn..

  • format_list_bulleted BS
  • · 2024. 2. 28.
  • textsms

Bitterroot Bio and Biotheus Forge Partnership for Bispecific Protein Development in Cardiovascular Immunotherapy

Bitterroot Bio and Biotheus Forge Partnership for Bispecific Protein Development in Cardiovascular Immunotherapy Overview Company: Bitterroot Bio; Biotheus Indication: Cardiovascular diseases Drug: N/A Trial Phase: N/A NCT ID: N/A Details In a significant stride within the field of cardio-immunology, Bitterroot Bio and Biotheus have publicly announced the establishment of a multi-year research c..

  • format_list_bulleted BS
  • · 2024. 2. 28.
  • textsms

Phylos and People Science Reveal Clinical Study Outcomes Demonstrating the Stimulating Impact of Tetrahydrocannabivarin (THCV) on Energy Levels

Pharmacological News: THCV's Energizing Impact Overview Company: Phylos Indication: Energizing Effects Drug: Natural Natural THCV Trial Phase: N/A NCT ID: Not applicable Study Findings Phylos, a cannabis genetics company, along with People Science, has conducted an IRB-endorsed clinical study on THCV’s energizing effects. The study was placebo-controlled and double-blind and showed that Natural ..

  • format_list_bulleted BS
  • · 2024. 2. 28.
  • textsms

Third Pole Therapeutics Triumphs with eNOfit™ System EFS for Non-Hospital Treatment of Pulmonary Hypertension

Third Pole Therapeutics Triumphs with eNOfit™ System EFS for Non-Hospital Treatment of Pulmonary Hypertension Overview Company: Third Pole Therapeutics Indication: Pulmonary hypertension associated with Interstitial Lung Disease (ILD) Drug: eNOfit™ (Inhaled Nitric Oxide Delivery System) Trial Phase: N/A NCT ID: Not available Early Feasibility Study (EFS) Success Third Pole Therapeutics, a forefr..

  • format_list_bulleted BS
  • · 2024. 2. 28.
  • textsms

Baseimmune Secures $11.3 Million Series A Investment for Accelerated Development of AI-Designed Cross-Protective Vaccines

Baseimmune Secures $11.3 Million Series A Investment for Accelerated Development of AI-Designed Cross-Protective Vaccines Company: Baseimmune Indication: - African swine fever - Coronavirus - Malaria Drug: AI-designed cross-protective vaccine candidates Trial Phase: N/A NCT ID: N/A Overview Baseimmune is a biotechnological firm committed to leading vaccine innovation using a proprietary artifici..

  • format_list_bulleted BS
  • · 2024. 2. 27.
  • textsms

Hoth Therapeutics Advances Preclinical Development of HT-KIT With Altasciences Collaboration for Mast Cell-Derived Cancer Treatment

Hoth Therapeutics Advances Preclinical Development of HT-KIT With Altasciences Collaboration for Mast Cell-Derived Cancer Treatment Overview Company: Hoth Therapeutics, Inc. Indication: Mast Cell-Derived Cancers Drug: HT-KIT Trial Phase: Preclinical (N/A for IND-enabling studies) Nct ID: Not applicable Development Update Hoth Therapeutics, Inc., a patient-focused biopharmaceutical company, has a..

  • format_list_bulleted BS
  • · 2024. 2. 27.
  • textsms

Commencement of the CONVERT II Pivotal Trial for AeriSeal® System: A Landmark Study by Pulmonx Corporation Aiming to Treat Severe COPD/Emphysema Patients

Commencement of the CONVERT II Pivotal Trial for AeriSeal® System: A Landmark Study by Pulmonx Corporation Aiming to Treat Severe COPD/Emphysema Patients Overview Company: Pulmonx Corporation Indication: Chronic Obstructive Pulmonary Disease (COPD)/Emphysema Drug: AeriSeal® System followed by Zephyr® Valves Trial Phase: N/A NCT ID: NCT06035120 Trial Initiation Details Pulmonx Corporation, a glob..

  • format_list_bulleted BS
  • · 2024. 2. 27.
  • textsms